Literature DB >> 27085758

Rates of and Reasons for Hospital Readmissions in Patients With Cirrhosis: A Multistate Population-based Cohort Study.

Elliot B Tapper1, Brian Halbert2, Jessica Mellinger3.   

Abstract

BACKGROUND & AIMS: There have been few population-based studies of the rates of and reasons for readmission to the hospital within 30 days among patients with cirrhosis.
METHODS: We identified all adult patients with cirrhosis who were admitted in 2011 to hospitals in California, Florida Massachusetts, Mississippi, New York, and Washington (119,722 unique index admissions with cirrhosis). We analyzed data from the State Inpatient Databases, which are longitudinal all-payer databases. Data were linked to the American Hospital Association's national survey for hospital characteristics. Outcomes included readmission to any hospital within 30 and 90 days, and the reasons for readmission.
RESULTS: The 30- and 90-day rates of readmission were 12.9% and 21.2% overall, with limited variation among states. Among patients with more than 3 complications of cirrhosis, 24.2% were readmitted within 30 days and 35.9% were readmitted within 90 days. The presence of hepatic encephalopathy was most strongly associated with readmission within 30 and 90 days (odds ratio, 1.77 for each). Almost 1 in every 4 readmissions was to a different hospital than the one from which the patient was discharged. Among patients with alcoholic liver disease and a history of a complications of cirrhosis, the 2 most common reasons for readmission were acute complications of cirrhosis (in 41.7%) and substance abuse (in 25.0%). Conversely, the most common reasons for readmission of patients with a history of complications of cirrhosis without alcoholic liver disease were acute complications (in 41.0%) and cancer complications (in 16.2%).
CONCLUSIONS: A high proportion of patients with cirrhosis are readmitted to the hospital (often to a different hospital) within 30 or 90 days; encephalopathy is most strongly associated with readmission. Reasons for readmission differ based on the cause of liver disease, and there are opportunities for quality improvement.
Copyright © 2016 AGA Institute. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Ascites; Hepatic encephalopathy; Hepatology; Liver Disease

Mesh:

Year:  2016        PMID: 27085758     DOI: 10.1016/j.cgh.2016.04.009

Source DB:  PubMed          Journal:  Clin Gastroenterol Hepatol        ISSN: 1542-3565            Impact factor:   11.382


  63 in total

1.  Outcomes after hepatic encephalopathy in population-based cohorts of patients with cirrhosis.

Authors:  Elliot B Tapper; Devin Aberasturi; Zhe Zhao; Chia-Yang Hsu; Neehar D Parikh
Journal:  Aliment Pharmacol Ther       Date:  2020-05-03       Impact factor: 8.171

Review 2.  Optimizing medication management for patients with cirrhosis: Evidence-based strategies and their outcomes.

Authors:  Mary J Thomson; Anna S Lok; Elliot B Tapper
Journal:  Liver Int       Date:  2018-06-19       Impact factor: 5.828

3.  Coordination of Care Is Associated With Survival and Health Care Utilization in a Population-Based Study of Patients With Cirrhosis.

Authors:  Shirley Cohen-Mekelburg; Akbar K Waljee; Brooke C Kenney; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2020-01-09       Impact factor: 11.382

4.  Risk Trajectories for Readmission and Death After Cirrhosis-Related Hospitalization.

Authors:  Aylin Tansel; Jennifer Kramer; Hua Feng; Hashem B El-Serag; Fasiha Kanwal
Journal:  Dig Dis Sci       Date:  2019-01-23       Impact factor: 3.199

Review 5.  Contemporary Epidemiology of Cirrhosis.

Authors:  Jad A Baki; Elliot B Tapper
Journal:  Curr Treat Options Gastroenterol       Date:  2019-06

6.  Fecal Microbial Transplant Capsules Are Safe in Hepatic Encephalopathy: A Phase 1, Randomized, Placebo-Controlled Trial.

Authors:  Jasmohan S Bajaj; Nita H Salzman; Chathur Acharya; Richard K Sterling; Melanie B White; Edith A Gavis; Andrew Fagan; Michael Hayward; Mary L Holtz; Scott Matherly; Hannah Lee; Majdi Osman; Mohammad S Siddiqui; Michael Fuchs; Puneet Puri; Masoumeh Sikaroodi; Patrick M Gillevet
Journal:  Hepatology       Date:  2019-06-18       Impact factor: 17.425

7.  Targets to improve quality of care for patients with hepatic encephalopathy: data from a multi-centre cohort.

Authors:  Jasmohan S Bajaj; Jacqueline G O'Leary; Puneeta Tandon; Florence Wong; Patrick S Kamath; Scott W Biggins; Guadalupe Garcia-Tsao; Jennifer Lai; Michael B Fallon; Paul J Thuluvath; Hugo E Vargas; Benedict Maliakkal; Ram M Subramanian; Leroy R Thacker; K Rajender Reddy
Journal:  Aliment Pharmacol Ther       Date:  2019-04-29       Impact factor: 8.171

Review 8.  Contemporary Epidemiology of Chronic Liver Disease and Cirrhosis.

Authors:  Andrew M Moon; Amit G Singal; Elliot B Tapper
Journal:  Clin Gastroenterol Hepatol       Date:  2019-08-08       Impact factor: 11.382

9.  Readmission Rates and Associated Outcomes for Alcoholic Hepatitis: A Nationwide Cohort Study.

Authors:  Adeyinka C Adejumo; George Cholankeril; Umair Iqbal; Eric R Yoo; Brian C Boursiquot; Waldo C Concepcion; Donghee Kim; Aijaz Ahmed
Journal:  Dig Dis Sci       Date:  2019-08-01       Impact factor: 3.199

10.  Predicting Overt Hepatic Encephalopathy for the Population With Cirrhosis.

Authors:  Elliot B Tapper
Journal:  Hepatology       Date:  2019-05-10       Impact factor: 17.425

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.